Brief: Aditxt Forms Adimune As Wholly Owned Subsidiary, Appoints Dr. Kapp As Its CEO

Aditxt

03/01/2023 14:21

Jan 3 (Reuters) - Aditxt Inc  ADTX.O :
    * ADITXT FORMS ADIMUNE, INC. AS A WHOLLY OWNED SUBSIDIARY
WITH A
FOCUS ON IMMUNE MODULATION THERAPIES AND APPOINTS DR. FRIEDRICH
KAPP, FORMER PRESIDENT OF THE THERAPEUTIC BUSINESS UNIT AT
SCHERING AG, AS ITS CHAIRMAN AND CEO
    * ADITXT INC - COMPLETION OF GMP DRUG SUBSTANCES IN JANUARY
FOR
CLINICAL TRIALS IN H2, 2023
    * ADITXT - CTA APPLICATION WILL REQUEST APPROVAL FOR ADIMUNE
TO
CONDUCT FIRST-IN-HUMAN STUDY IN PSORIASIS PATIENTS, BEGINNING IN
SECOND HALF OF 2023
    * ADITXT INC - SECOND STUDY IS ALSO PLANNED FOR TYPE 1
DIABETES

Source text for Eikon:  ID:nBw2BnVjMa 
Further company coverage:  ADTX.O 
 ((Reuters.Briefs@thomsonreuters.com;))